Dr. Tananbaum is the founding CEO of Foresite Capital Management.He has led investments in 21 successful healthcare companies, including Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Amerigroup and Jazz Pharmaceuticals.Previously, Dr. Tananbaum founded and held management positions at GelTex Pharmaceuticals (acquired by Genzyme for $1.6B) and Theravance.He holds an M.D. from Harvard Medical School and an M.B.A from Harvard Business School, and a B.S. and B.S.E.E. from Yale University.Dr. Tananbaum has served on the advisory boards and/or visiting committees to the Harvard-MIT HST program and Yale School of Engineering.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
HealthVerity | Board Member | Apr 5, 2019 | — | Detail |
Element Biosciences | Board Member | — | — | Detail |